Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03153371
Other study ID # 1RF1AG050967
Secondary ID UCLA IRB#16-0004
Status Recruiting
Phase
First received
Last updated
Start date April 4, 2016
Est. completion date March 31, 2022

Study information

Verified date April 2020
Source University of California, Los Angeles
Contact Youssef I Khattab, BA
Phone (310)-478-3711
Email YKhattab@mednet.ucla.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.


Description:

Unlike the usual late-onset Alzheimer's disease (LOAD), early-onset AD (EOAD), with onset before age 65, includes a high percentage of phenotypic variants. These non-familial, variants (vEOAD) present, not with progressive memory loss, but with language, visuospatial, or other cognitive difficulties. AD is now understood as a disorder that manifests with disturbed cognition reflecting disturbed neural networks. A multivariate analysis of neuropsychological tests, the "gold standard" for objectively defining neurocognitive impairments, coupled with structural and functional neuroimaging analysis of connectomes, can identify the neurocognitive-neural network profiles of vEOAD patients, compared to those with typical AD. This knowledge can increase our understanding of the heterogeneity of AD and how it causes disease.

This study hopes to show that vEOAD constitutes a "Type 2 AD", by (1) defining the neuropsychological components of Type 2 AD, and (2) understanding the anatomy and atrophy of the brains of vEOAD patients. Together, these components can outline the neurocognitive-neural network profile of Type 2 AD.

In addition to information that can help in the diagnosis and management of EOAD, this study can stimulate novel research into the reasons for this neurobiological heterogeneity in AD and could potentially lead to interventions based on alternate neurocognitive-neural network profiles.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date March 31, 2022
Est. primary completion date March 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 85 Years
Eligibility - Inclusion criteria for patients with Alzheimer's disease (AD):

1. Meet criteria for AD.

2. Meet clinical criteria for either typical amnestic AD or variant phenotypes of early-onset (EOAD, or "Type 2 AD").

3. Mild-moderate dementia severity

4. Sufficient English fluency to complete neuropsychological testing in English.

5. Ability to provide consent for participation, or willingness to provide assent and a legally-authorized representative willing to provide surrogate consent.

6. Availability of a caregiver informant for participation

- Exclusion criteria for patients with Alzheimer's disease (AD):

1. Complicating medical illnesses.

2. Significant primary visual impairments.

3. Major psychiatric illness not due to the dementia.

4. Confounding medications.

- Inclusion criteria for control participants:

1. Score 28/30 or higher on the Folstein Mini-Mental Status Exam.

2. Age 40-85 years old

3. Able to provide consent for participation and express willingness to participate in one-year follow-up visits.

4. Have sufficient English fluency to complete neuropsychological testing in English.

- Exclusion criteria for control participants:

1. Complicating medical illnesses.

2. Significant primary visual impairments.

3. Major psychiatric illness not due to the dementia.

4. Confounding medications.

Study Design


Locations

Country Name City State
United States UCLA Department of Neurology Los Angeles California

Sponsors (3)

Lead Sponsor Collaborator
University of California, Los Angeles National Institute on Aging (NIA), University of Southern California

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Alzheimer's disease Subtype Neuropsychological testing results for use in a two-stage multivariate diagnostic method that combines the (weighted) test results in order to best discriminate Type 2 AD and typical AD. Performed at baseline
Secondary Change in overall Neurological profile Change in performance on neurological tasks between baseline visit and follow-up visit. Performed at baseline and 1-year follow-up visit
Secondary Brain atrophy in MRI - Magnetic Resonance Imaging of the brain Images from initial MRI scan taken at baseline visit will be analyzed for atrophy and white matter tract integrity Performed at baseline visit
Secondary Change in overall Neuropsychological profile Change in neuropsychological performance over time. Performed at baseline and 1-year follow-up visit
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A